Galecto Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 2

Employees

  • Stock Symbol
  • GLTO

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $4.78
  • (As of Friday Closing)

Galecto General Information

Description

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Contact Information

Website
www.galecto.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Ole Maaloes Vej 3
  • 2200 Copenhagen
  • Denmark
+45 70
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Ole Maaloes Vej 3
  • 2200 Copenhagen
  • Denmark
+45 70

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Galecto Stock Performance

As of 14-Feb-2025, Galecto’s stock price is $4.78. Its current market cap is $6.3M with 1.32M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.78 $4.58 $4.24 - $23.50 $6.3M 1.32M 19K -$19.11

Galecto Financials Summary

As of 30-Sep-2024, Galecto has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (7,619) (24,193) (38,808) (24,662)
Revenue 0 0 0 0
EBITDA (21,616) (39,208) (61,856) (51,467)
Net Income (21,173) (38,349) (61,624) (51,752)
Total Assets 23,376 38,227 73,188 122,215
Total Debt 32 249 804 847
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Galecto Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Galecto‘s full profile, request access.

Request a free trial

Galecto Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processe
Drug Discovery
Copenhagen, Denmark
2 As of 2024

Waltham, MA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Galecto Competitors (53)

One of Galecto’s 53 competitors is Morphic Therapeutic, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Morphic Therapeutic Formerly VC-backed Waltham, MA
Pliant Therapeutics Formerly VC-backed San Francisco, CA
Syntara Formerly VC-backed Frenchs Forest, Australia
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Marinus Pharmaceuticals Formerly VC-backed Radnor, PA
You’re viewing 5 of 53 competitors. Get the full list »

Galecto Patents

Galecto Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240059728-A1 Novel galactoside inhibitor of galectins Pending 10-Feb-2021
CA-3203618-A1 Novel galactoside inhibitor of galectins Pending 28-Dec-2020
EP-4267568-A1 Novel galactoside inhibitor of galectins Pending 28-Dec-2020
US-20240309038-A1 Novel galactoside inhibitor of galectins Pending 28-Dec-2020
CA-3205493-A1 Novel galactoside inhibitor of galectins Pending 22-Dec-2020 C07D417/14
To view Galecto’s complete patent history, request access »

Galecto Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Galecto Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Galecto‘s full profile, request access.

Request a free trial

Galecto Investments & Acquisitions (2)

Galecto’s most recent deal was a Corporate Asset Purchase with Bridge Medicines (Global Rights to BRM-1420). The deal was made on 07-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bridge Medicines (Global Rights to BRM-1420) 07-Oct-2024 Corporate Asset Purchase Buildings and Property
PharmAkea Therapeutics 31-Dec-2019 Merger/Acquisition Biotechnology
To view Galecto’s complete investments and acquisitions history, request access »

Galecto ESG

Risk Overview

Risk Rating

Updated April, 20, 2023

33.01 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 16,048

Rank

Percentile

Pharmaceuticals

Industry

of 914

Rank

Percentile

Pharmaceuticals

Subindustry

of 451

Rank

Percentile

To view Galecto’s complete esg history, request access »

Galecto FAQs

  • When was Galecto founded?

    Galecto was founded in 2011.

  • Where is Galecto headquartered?

    Galecto is headquartered in Copenhagen, Denmark.

  • What is the size of Galecto?

    Galecto has 2 total employees.

  • What industry is Galecto in?

    Galecto’s primary industry is Drug Discovery.

  • Is Galecto a private or public company?

    Galecto is a Public company.

  • What is Galecto’s stock symbol?

    The ticker symbol for Galecto is GLTO.

  • What is the current stock price of Galecto?

    As of 14-Feb-2025 the stock price of Galecto is $4.78.

  • What is the current market cap of Galecto?

    The current market capitalization of Galecto is $6.3M.

  • Who are Galecto’s competitors?

    Morphic Therapeutic, Pliant Therapeutics, Syntara, Dicerna Pharmaceuticals, and Marinus Pharmaceuticals are some of the 53 competitors of Galecto.

  • What is Galecto’s annual earnings per share (EPS)?

    Galecto’s EPS for 12 months was -$19.11.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »